Autolus Therapeutics (AUTL) Scheduled to Post Quarterly Earnings on Tuesday

Autolus Therapeutics (NASDAQ:AUTL) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 14th. Analysts expect Autolus Therapeutics to post earnings of ($0.10) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, March 14th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.18). On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Stock Down 2.6 %

NASDAQ AUTL opened at $4.08 on Tuesday. The company has a 50-day simple moving average of $5.33 and a two-hundred day simple moving average of $5.27. Autolus Therapeutics has a 12-month low of $1.79 and a 12-month high of $7.45. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -3.43 and a beta of 2.03.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AUTL. Truist Financial raised their price target on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Friday, April 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.70.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.